Edinburgh-based gene therapy developer Synpromics has signed a new collaboration deal to develop novel gene therapies for blood-based disorders. The collaboration between Synpromics and the University College London’s Great Ormond Street Institute of Child Health will work to develop therapies for pathologies affecting the haematopoietic system – the system of organs and tissues in the body which produce cellular blood components. The aim is to...
Synpromics Ltd, the leader in gene control, today announced the appointment of Sarah Haecker Meeks, PhD to the position of Vice President, Business Development. Dr. Haecker Meeks brings a deep expertise in emerging technologies and business strategy focused on the design and development of gene medicines and will lead business development for the company. Synpromics has also established a new US subsidiary, Synpromics Inc. and...
New University of Glasgow research published today (January 15) in the journal PNAS, shows a robot equipped with artificial intelligence was able to build unstable oil-in-water droplets as models for new artificial life forms. It was also able to predict their properties ahead of time even though conventional physical methods failed to do so. Professor Lee Cronin, the University’s Regius Chair of Chemistry, said: “This work...
Bacteria which lives in the human gut could hold the key to finding an efficient way to capture and store carbon dioxide, scientists have found. Cutting carbon dioxide (CO2) emissions to slow down or even reverse global warming is one of the biggest challenges humankind faces. New ways of capturing and storing CO2 will be needed, and researchers at Dundee University have shown E. coli...
Scottish biotech TC BioPharm enters into a collaboration and license agreement with bluebird bio (NASDAQ:BLUE) aimed at advancing the former’s CAR-engineered gamma delta T cell program into the clinic and expanding blood cancer and solid tumor targets. The collaboration teams up Bluebird bio, who are one of several companies working on safer versions of CAR-T cells and TC BioPharm who are developing CAR-T technology called ImmuniCAR which uses gene therapy to...
NovaBiotics, the clinical-stage anti-infectives biotechnology company, has been named Most Innovative EU Biotech SME at EuropaBio’s 8th Annual SME Awards in Brussels, recognising the Company’s innovation in tackling Antimicrobial Resistance (AMR) as one of our greatest global health challenges. NovaBiotics is a leading innovator in the anti-infectives space and have gone back to the drawing board to develop a novel approach to antibacterial and antifungal...